Match!
Vikram Pattanayak
Harvard University
Genome editingMolecular biologyGeneticsDNABiology
30Publications
11H-index
3,216Citations
What is this?
Publications 23
Newest
#1Yuhree Kim (Harvard University)H-Index: 1
#2David Wojciechowski (Harvard University)H-Index: 11
Last. Maryam M. Asgari (Harvard University)H-Index: 30
view all 5 authors...
ABSTRACT Keratinocyte carcinoma (KC) defined as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is the most common malignancy among non-Hispanic white (NHW) renal transplant recipients (RTRs). While recent genome-wide association studies reported that the class II human leukocyte antigen (HLA) is associated with KC risk, epidemiologic data on HLA type and KC risk in RTRs is limited. Using an institutional cohort of NHW RTRs transplanted between 1993-2017, we examined the association...
Source
#1Sarah E. Turbett (Harvard University)H-Index: 5
#2Melis N. Anahtar (Harvard University)H-Index: 9
Last. John A. Branda (Harvard University)H-Index: 19
view all 11 authors...
BACKGROUND: Anaplasmosis presents with fever, headache, and laboratory abnormalities including leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) is the preferred diagnostic but is overutilized. We determined if routine laboratory tests could exclude anaplasmosis, improving PCR utilization. METHODS: Anaplasma PCR results from a 3-year period, with associated complete blood count (CBC) and liver function test (LFT) results, were retrospectively reviewed. PCR rejection criteria, base...
Source
#1Melis N. Anahtar (Harvard University)H-Index: 9
#2Vikram Pattanayak (Harvard University)H-Index: 11
Last. Sarah E. Turbett (Harvard University)H-Index: 5
view all 10 authors...
Source
#1Grace K. Mahowald (Harvard University)H-Index: 9
#2Brendan J. Kimball (Harvard University)H-Index: 1
Last. Vikram Pattanayak (Harvard University)H-Index: 11
view all 6 authors...
Aim Beginning on March 25, 2015, our institution’s kidney transplant program has implemented a “readiness” protocol, whereby patients are listed after limited workup and comprehensive testing is deferred until the anticipated time to transplantation is approximately 6–12 months. Prior to implementation of this protocol, our histocompatibility laboratory would receive monthly sera for anti-HLA antibody screening immediately upon listing. However, as part of the readiness strategy, the lab now req...
Source
#1Yuhree Kim (Harvard University)H-Index: 1
#2Vikram Pattanayak (Harvard University)H-Index: 11
Last. Maryam M. Asgari (Harvard University)H-Index: 30
view all 5 authors...
Source
#1Caleb A. LareauH-Index: 18
#2Kendell ClementH-Index: 18
Last. Luca PinelloH-Index: 26
view all 7 authors...
16 CitationsSource
#1Caleb A. Lareau (Harvard University)H-Index: 18
#2Kendell Clement (Harvard University)H-Index: 18
Last. Luca Pinello (Harvard University)H-Index: 26
view all 7 authors...
Schaefer et al. recently advanced the provocative conclusion that CRISPR-Cas9 nuclease can induce off-target alterations at genomic loci that do not resemble the intended on-target site. Using high-coverage whole genome sequencing (WGS), these authors reported finding SNPs and indels in two CRISPR-Cas9-treated mice that were not present in a single untreated control mouse. On the basis of this association, Schaefer et al. concluded that these sequence variants were caused by CRISPR-Cas9. This ne...
7 CitationsSource
#2Michelle S. PrewH-Index: 6
Last. Martin J. AryeeH-Index: 40
view all 8 authors...
#1Benjamin P. Kleinstiver (Harvard University)H-Index: 17
#2Vikram Pattanayak (Harvard University)H-Index: 11
Last. J. Keith Joung (Harvard University)H-Index: 68
view all 6 authors...
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations at genomic locations that resemble the intended target. These so-called off-target effects can confound research applications and are important considerations for potential therapeutic use. Existing strategies for reducing genome-wide off-targets of the broadly used Streptococcus pyogenes Cas9 (SpCas9) have thus far proven to be imperfect by possessing only partial efficacy and/or other limitati...
11 CitationsSource
#1Benjamin P. Kleinstiver (Harvard University)H-Index: 17
#2Vikram Pattanayak (Harvard University)H-Index: 11
Last. J. Keith Joung (Harvard University)H-Index: 68
view all 7 authors...
A high-fidelity variant of Streptococcus pyogenes CRISPR–Cas9 is reported that lacks detectable off-target events as assessed by genome-wide break capture and targeted sequencing methods.
947 CitationsSource
123